Source: Eye Future ；Editor: SophiaReprint Requirements: Can be reprinted 24 hours after the first publication, source must be credited.
Global Ophthalmology Conference Registration
Recently,Johnson & Johnson (NYSE: JNJ)AnnouncementAppointment of Shawn Millerick asPresident of Americas Vision Care Business, hoping that Millerick will be committed to achieving the maximum growth in vision care and surgical vision business.Shawn Millerick, former Vice President of Marketing at Abbott Group, will be responsible for...Develop strategies and drive growth for Johnson & Johnson's vision care product portfolio in North America and Latin America., which includes the globally leading ACUVUE series of contact lenses.
Shawn Millerick
Shawn Millerick will focus onAccelerate Digital Transformation, to optimize treatment outcomes for patients and eye care professionals. Johnson & Johnson emphasized Millerick's extensive experience in vision care and healthcare, including commercial strategy, enterprise solutions, consumer health, and over-the-counter (OTC) marketing knowledge, with a particular focus on shopper marketing and category insights.Chairman of Johnson & Johnson Medical Technology Group Vision BusinessPeter Menziuso "I am delighted to have Millerick join us and lead Johnson & Johnson Medical's vision care business in North America and Latin America. Millerick’s exceptional leadership and deep expertise will be a transformative catalyst for the future development of Johnson & Johnson Medical. Millerick’s experience covers...Business strategy and corporate solutions, as well as extensive consumer healthcare experience, and is proficient in over-the-counter drug marketing, focusing on shopper marketing and category insights.
The appointment of Shawn Millerick heraldsJohnson & Johnson's vision care business in the Americas is entering a new growth phase focused on innovation, digital transformation, and collaboration.。
# Performance Pressure Becomes Main Cause of Executive TurnoverJohnson & Johnson's ophthalmic medical devices are mainly included under the Vision of Johnson & Johnson., whose business structure covers two core parts:
(1) Ophthalmic implants, surgical medical devices and consumables, etc., which are uniformly categorized as"Advanced Vision", focusing on providingOphthalmic SurgeryProvide comprehensive support;
(II) Products such as contact lenses, contact lens care solutions, and eye drops, this field is called"Vision Health", Aiming to provide comfortableVision Correction and Care SolutionsIn addition, the ophthalmic prescription drug business belongs to Johnson & Johnson's pharmaceuticals sector, providing patients with a variety of treatment options.
According to the 2024 quarterly financial report released by Johnson & Johnson Vision, the global revenue for the first quarter of 2024 totaled $1.258 billion.Compared to USD 1.30 billion in the same period of 2023Decrease by 3.3%; Total global revenue in the second quarter of 2024 was $1.285 billion,Compared to $1.308 billion in the second quarter of 2023Decreased by 1.7%；The Third Quarter of 2024Global revenue totaled $1.3 billion,Compared to $1.256 billion in the third quarter of 2023Increase by 3.5%。For Vision Surgical BusinessGlobal revenue in the first quarter of 2024 totaled $348 million, increasing by 0.3% from $347 million in the first quarter of 2023. Among this,U.S. revenue was $110 million, compared to $114 million in the first quarter of 2023.Down 3.7%, while revenue outside the United States was $238 million, an increase of 2.2% compared to $233 million in the first quarter of 2023.Total global revenue in the second quarter of 2024 was US$367 million, a decrease of 0.5% compared to US$369 million in the second quarter of 2023. Among this,U.S. revenue was $113 million, compared to $120 million in the second quarter of 2023.Down 5.8%, while revenue outside the United States was $254 million, representing a 2.1% increase from $249 million in the second quarter of 2023.Total global revenue in the third quarter of 2024 was US$333 million, representing a 1.3% increase from US$328 million in the third quarter of 2023.U.S. revenue decreased from $112 million to $108 million,Decreased by 3.6%Revenue from outside the United States was $2.25 billion, an increase of 3.9% compared to $2.16 billion in the third quarter of 2023.For contact lens businessGlobal Contact Lens Sales in the First Quarter of 2024 Were $910 Million, a 4.6% Decrease from $953 Million in the First Quarter of 2023.U.S. revenue was $438 million, compared to $444 million in the first quarter of 2023.Down 1.4%Revenue outside the United States was $472 million, a decrease of 7.4% compared to $509 million in the first quarter of 2023.Global Contact Lens Sales in Q2 2024 Reach $918 Million, Down 2.2% from $939 Million in Q2 2023.U.S. revenue was $409 million, compared to the second quarter of 2023Hold BalanceRevenue outside the United States was $509 million, a decrease of 4.0% compared to $530 million in the second quarter of 2023.Global Contact Lens Sales in Q3 2024 Reach $968 Million, Up 4.2% from $928 Million in Q3 2023U.S. revenue was $441 million, compared to $399 million in the third quarter of 2023.Increase by 10.2%Revenue outside the United States was $527 million, a decrease of 0.3% compared to $529 million in the third quarter of 2023.Facing fierce market competition and constantly changing market conditions, Johnson & Johnson's executive changes have naturally become more frequent under the pressure of performance.。# Multiple Senior Executives Have Resigned SuccessivelyMay 2024,Johnson & Johnson VisionAsia-Pacific RegionThe president notified by email,Johnson & Johnson's eye health business has seen multiple senior executives resign simultaneously.The following is the original content of the company's email notification:Today, I would like to share with you: after serving Johnson & Johnson for nearly 10 years,Johnson & Johnson Vision's Vice President for Mainland China and Hong Kong, Wang Liping, to Step Down Soon。We will announce the successor to this position at a later date.Although there have been adjustments in the management, we will always remain committed to becoming the leading force in China's eye health market.”"I would like to share with you:Johnson & Johnson Vision China's Cataract Division Head, Wang Jiyan, to Step DownJi Yan has worked at Johnson & Johnson for 20 years and recently led the cataract product-related business in the Chinese market. We will announce the successor to this position at a later date."“National Sales Director Chen ZhipingThe confirmed last working day is 2024/05/14.Now entering the resignation settlement process。”It is worth noting that,2024April 23,Song, Chairman of Johnson & Johnson China and President of Johnson & Johnson Medical Technology ChinaFor the GroupSubmit a resignation, seeking external development opportunities.July 25,Edward Zhou (Zhou Mintao) will serve as the President of Johnson & Johnson Medical Technology, China.Meanwhile, Zhou Mintao will become one of the members of the Johnson & Johnson Medical Technology Asia-Pacific leadership team.Zhou Mintao, President of Johnson & Johnson Medical Technology, China# Business Growth Points in ChinaAlthough the change of senior leadership at Johnson & Johnson's Vision Care in China may have a certain impact on the company’s operations and development, the financial reports show that Vision Care’s performance in China remains strong.
Johnson & Johnson VisionAs a leader in the global ophthalmology market, it has a wide range of business operations,Covering ophthalmic implants, surgical medical devices and consumables, as well as contact lenses, care solutions, and eye drops, etc.. The company has been committed to innovation and development in the field of ophthalmology, particularly achieving remarkable results in the treatment of cataracts.
Johnson & Johnson Vision launchedNew Generation Enhanced Continuous Vision Intraocular Lens Series, such as TECNIS Synergy andTECNIS Eyhance，Not only improved the patient's contrast sensitivity, but also reduced optical interference, providing patients with a higher quality visual experience.In the diagnosis and treatment of ocular surface diseases, a solution for the diagnosis and treatment of meibomian gland dysfunction has been introduced.LipiView Ocular Surface Interferometer and LipiFlow Thermal Pulsation System for Meibomian Glandetc.
As a leader in China's ophthalmology field,Johnson & Johnson Vision closely collaborates with leading institutions such as Aier Eye Hospital to jointly promote the implementation of the "Foresee" initiative.. This initiative aims to pilot new products and technologies in specific areas such as Boao Lecheng, offering patients more advanced and personalized treatment options.
In addition,Johnson & Johnson Vision actively devotes itself to raising public awareness and importance of eye health.By participating in activities such as Guinness World Records challenges, the company calls on more people to pay attention to eye health and understand the hazards and preventive measures of eye diseases.
In terms of introducing innovative products and technologiesJohnson & Johnson Vision Leads Cataract Treatment Innovation, Launches VERITAS™ Phacoemulsification System and TECNIS PureSee™ IOL, Precisely Enhancing Cataract Treatment in China and Improving Patient Experience and Postoperative Outcomes.In the construction of the ophthalmology ecosystem：Johnson & Johnson Vision Partners with Leica Microsystems to Build an Ophthalmic Ecosystem, integrate medical resources channels, broaden the ophthalmic service areas, popularize scientific eye health knowledge, and inject new momentum into the long-term development of China's ophthalmology industry.In the field of refractive cataract collaboration：Johnson & Johnson Vision Partners with Zhejiang University Eye Hospital to Forge Global Strategic Alliance, jointly promoting new ophthalmic technologies and products in the Chinese market, building industry consensus, standardizing the clinical application of intraocular lenses, and contributing to the academic prosperity of the ophthalmic cataract field.In terms of collaboration with ophthalmic medical institutions in China：Johnson & Johnson Vision partners with leading ophthalmic institutions in China, including He Eye Specialist Hospital, Huaxia Eye Hospital Group, and Hong Kong CMER International Eye Care Group., jointly build a strategic cooperation bridge, promote the widespread application of new ophthalmic technologies and products in China, and help elevate the level of ophthalmic diagnosis and treatment to a new height.
